CX-4945 Clinical Trials (2026): 6 Studies for Multiple Myeloma & Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 CX-4945 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Multiple Myeloma & Breast Cancer) and 304 total planned enrollment. Most recent activity: NCT06202521 (Apr 2025).
CX-4945 clinical trials at a glance: phase × recruitment status
| Phase | completed | terminated | unknown | Total |
|---|---|---|---|---|
| P1 | 2 | 2 | 4 | |
| P1/P2 | 1 | 1 | ||
| P2 | 1 | 1 |
CX-4945 clinical trials by indication
Community-acquired Pneumonia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06202521 | — | P2 | terminated | CX-4945 in Viral Community Acquired Pneumonia |
COVID-19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05817708 | CX-4945 | P1 | completed | A Study of Silmitasertib (CX-4945) in Healthy Subject |
Carcinoma, Basal Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03897036 | BCC | P1 | completed | Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) |
Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02128282 | — | P1/P2 | completed | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma |
Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01199718 | — | P1 | unknown | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00891280 | — | P1 | unknown | Dose-escalation Study of Oral CX-4945 |
Terminated and withdrawn CX-4945 trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06202521terminatedCX-4945 in Viral Community Acquired Pneumonia
All CX-4945 trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06202521 | CX-4945 in Viral Community Acquired Pneumonia | P2 | terminated | 45 | Senhwa Biosciences, Inc. | Mar 2024 | |
| NCT03897036 | BCC | Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) | P1 | completed | 25 | Senhwa Biosciences, Inc. | Apr 2019 |
| NCT05817708 | CX-4945 | A Study of Silmitasertib (CX-4945) in Healthy Subject | P1 | completed | 30 | Senhwa Biosciences, Inc. | Nov 2022 |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | P1/P2 | completed | 127 | Senhwa Biosciences, Inc. | Jun 2014 | |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | P1 | unknown | 55 | Cylene Pharmaceuticals | Feb 2009 | |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | P1 | unknown | 22 | Cylene Pharmaceuticals | Sep 2010 |
CX-4945 clinical trials: frequently asked questions
- How many CX-4945 clinical trials are there?
- 6 CX-4945 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are marked completed.
- Are CX-4945 clinical trials recruiting in 2026?
- No active CX-4945 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is CX-4945 being studied for?
- CX-4945 is being studied for Multiple Myeloma, Breast Cancer, Carcinoma, Basal Cell, Castleman's Disease, Cholangiocarcinoma and 6 more. The trials are grouped by indication on this page.
- What phase is CX-4945 in?
- CX-4945 clinical trials span 1 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CX-4945 clinical trials?
- The lead sponsor across the most CX-4945 trials is Senhwa Biosciences, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CX-4945as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: